PREvention of MOther to child Transmission of HIV and Syphilis using an Electroc...
PREvention of MOther to child Transmission of HIV and Syphilis using an Electrochemical Readout based on DNA Switches
Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
PHOCNOSIS
Advanced nanophotonic point of care analysis device for fast...
4M€
Cerrado
AB-SWITCH
Evaluation of commercial potential of a low cost kit based o...
150K€
Cerrado
CTQ2014-58643-R
LABS-ON-A-CHIP INTEGRANDO NANOMATERIALES Y MICROMOTORES BASA...
134K€
Cerrado
PLEC2021-007727
Nanobiosensor multiplexado para el diagnóstico instantáneo y...
317K€
Cerrado
MAT2012-38573-C02-01
PLATAFORMAS DE DIAGNOSTICO UNIVERSAL BASADAS EN NANOPARTICUL...
121K€
Cerrado
NIMM
Fluorescence based nano immunoassay IVD platform
150K€
Cerrado
Información proyecto PREMOTHER
Duración del proyecto: 33 meses
Fecha Inicio: 2018-03-15
Fecha Fin: 2021-01-06
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
Mother-to-child transmission of HIV and Syphilis causes approximately 305,000 fetal and neonatal deaths every year and leaves 215,000 infants at increased risk of dying from prematurity, low-birth-weight or congenital disease. An accurate diagnosis of diagnostic-antibodies and a simple treatment during the first weeks of pregnancy could stop all those deaths.
Here, I propose the development of a new technique to be used to measure antibodies directly in whole blood. These will combine the multiplexed (i.e., multiple tests in parallel on one sample), quantitative performance of laboratory-based tests with the portability and low-cost of point-of-care tests. As the first step, I will design, optimize and test nanometer-scale, DNA-based switches that undergo a dramatic change in conformation (closed/open) upon recognizing its target antibody. I will use this conformational change to generate a large, easily measurable electronic (electrochemical) signal, which I will then employ in and validate as laboratory-scale, single-test devices using both purified antibodies and authentic human samples. I will then integrate the set of sensors exhibiting good clinical performances into a single, paper-based microfluidic sample handing device (similar to the home pregnancy test) to generate a low-cost platform capable of measuring multiple diagnostic antibodies in a single finger-prick blood sample.
The final and main goal in the DNA-SPADE project is the development of a working prototype diagnostic device, which I will design accordingly to suggestions/inputs from a variety of possible final users (such as nurses and doctors).